OBJECTIVE:Estrogen plus progestin therapy (EPT) in postmenopausal women increasesbreast cancer risk and mammographic density to a higher extent than does estrogen therapy alone. Data from the randomized placebo-controlled Postmenopausal Estrogen/Progestinv Interventions trial showed that EPT-induced increases in serum estrone and estrone sulfate levels were positively correlated with increases in mammographic density. Here, after adjusting for serum estrone and estrone sulfate levels, we investigated the roles of posttreatment serum progestogen increase and of progesterone receptor gene (PGR) genetic variations on changes in mammographic density. METHODS: We measured the percent mammographic density and serum progestogen levels in 280 Postmenopausal Estrogen/Progestin Interventions trial participants randomized to EPT treatment. Analyses of genetic variations in PGR were limited to 260 white women for whom we successfully obtained PGR genotypes. We used linear regression analyses to determine how an increase in progestogen levels and PGR genetic variation influenced mammographic density change after EPT. RESULTS: The increase in posttreatment serum progestogen level was positively associated with greater increases in mammographic density after adjustment for covariates (P trend = 0.044). Compared with women in the lowest quartile of serum progestogen level, women in the highest quartile experienced a 3.5% greater increase in mammographic density (P = 0.046). We did not find a strong indication that genetic variation in PGR was associated with mammographic density increase or modified the association with serum progestogen; however, confidence in these null findings is constrained by our small sample size. CONCLUSIONS: Our results suggest that higher serum progestogen levels resulting from EPT treatment lead to greater increases in mammographic density.
RCT Entities:
OBJECTIVE: Estrogen plus progestin therapy (EPT) in postmenopausal womenincreases breast cancer risk and mammographic density to a higher extent than does estrogen therapy alone. Data from the randomized placebo-controlled Postmenopausal Estrogen/Progestinv Interventions trial showed that EPT-induced increases in serum estrone and estrone sulfate levels were positively correlated with increases in mammographic density. Here, after adjusting for serum estrone and estrone sulfate levels, we investigated the roles of posttreatment serum progestogen increase and of progesterone receptor gene (PGR) genetic variations on changes in mammographic density. METHODS: We measured the percent mammographic density and serum progestogen levels in 280 Postmenopausal Estrogen/Progestin Interventions trial participants randomized to EPT treatment. Analyses of genetic variations in PGR were limited to 260 white women for whom we successfully obtained PGR genotypes. We used linear regression analyses to determine how an increase in progestogen levels and PGR genetic variation influenced mammographic density change after EPT. RESULTS: The increase in posttreatment serum progestogen level was positively associated with greater increases in mammographic density after adjustment for covariates (P trend = 0.044). Compared with women in the lowest quartile of serum progestogen level, women in the highest quartile experienced a 3.5% greater increase in mammographic density (P = 0.046). We did not find a strong indication that genetic variation in PGR was associated with mammographic density increase or modified the association with serum progestogen; however, confidence in these null findings is constrained by our small sample size. CONCLUSIONS: Our results suggest that higher serum progestogen levels resulting from EPT treatment lead to greater increases in mammographic density.
Authors: Linda K Weiss; Ronald T Burkman; Kara L Cushing-Haugen; Lynda F Voigt; Michael S Simon; Janet R Daling; Sandra A Norman; Leslie Bernstein; Giske Ursin; Polly A Marchbanks; Brian L Strom; Jesse A Berlin; Anita L Weber; David R Doody; Phyllis A Wingo; Jill A McDonald; Kathleen E Malone; Suzanne G Folger; Robert Spirtas Journal: Obstet Gynecol Date: 2002-12 Impact factor: 7.661
Authors: Marcia L Stefanick; Garnet L Anderson; Karen L Margolis; Susan L Hendrix; Rebecca J Rodabough; Electra D Paskett; Dorothy S Lane; F Allan Hubbell; Annlouise R Assaf; Gloria E Sarto; Robert S Schenken; Shagufta Yasmeen; Lawrence Lessin; Rowan T Chlebowski Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Celeste Leigh Pearce; Joel N Hirschhorn; Anna H Wu; Noël P Burtt; Daniel O Stram; Stanton Young; Laurence N Kolonel; Brian E Henderson; David Altshuler; Malcolm C Pike Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506
Authors: G A Greendale; B A Reboussin; A Sie; H R Singh; L K Olson; O Gatewood; L W Bassett; C Wasilauskas; T Bush; E Barrett-Connor Journal: Ann Intern Med Date: 1999-02-16 Impact factor: 25.391
Authors: Karen A Pooley; Catherine S Healey; Paula L Smith; Paul D P Pharoah; Deborah Thompson; Louise Tee; Judith West; Clare Jordan; Douglas F Easton; Bruce A J Ponder; Alison M Dunning Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-04 Impact factor: 4.254
Authors: Anne McTiernan; Rowan T Chlebowski; Christopher Martin; Jennifer David Peck; Aaron Aragaki; Etta D Pisano; C Y Wang; Karen C Johnson; Joann E Manson; Robert B Wallace; Mara Z Vitolins; Gerardo Heiss Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Anja Rudolph; Peter A Fasching; Sabine Behrens; Ursula Eilber; Manjeet K Bolla; Qin Wang; Deborah Thompson; Kamila Czene; Judith S Brand; Jingmei Li; Christopher Scott; V Shane Pankratz; Kathleen Brandt; Emily Hallberg; Janet E Olson; Adam Lee; Matthias W Beckmann; Arif B Ekici; Lothar Haeberle; Gertraud Maskarinec; Loic Le Marchand; Fredrick Schumacher; Roger L Milne; Julia A Knight; Carmel Apicella; Melissa C Southey; Miroslav K Kapuscinski; John L Hopper; Irene L Andrulis; Graham G Giles; Christopher A Haiman; Kay-Tee Khaw; Robert Luben; Per Hall; Paul D P Pharoah; Fergus J Couch; Douglas F Easton; Isabel Dos-Santos-Silva; Celine Vachon; Jenny Chang-Claude Journal: Breast Cancer Res Date: 2015-08-16 Impact factor: 6.466
Authors: Eunjung Lee; Jianning Luo; Fredrick R Schumacher; David Van Den Berg; Anna H Wu; Daniel O Stram; Leslie Bernstein; Giske Ursin Journal: BMC Cancer Date: 2018-11-06 Impact factor: 4.430
Authors: M J Schoemaker; E J Folkerd; M E Jones; M Rae; S Allen; A Ashworth; M Dowsett; A J Swerdlow Journal: Br J Cancer Date: 2014-02-11 Impact factor: 7.640
Authors: Merete Ellingjord-Dale; Eunjung Lee; Elisabeth Couto; Ali Ozhand; Samera Qureshi; Solveig Hofvind; David J Van Den Berg; Lars A Akslen; Tom Grotmol; Giske Ursin Journal: Breast Cancer Res Date: 2012-10-27 Impact factor: 6.466
Authors: Manila Hada; Hannah Oh; Shaoqi Fan; Roni T Falk; Berta Geller; Pamela Vacek; Donald Weaver; John Shepherd; Jeff Wang; Bo Fan; Sally Herschorn; Louise A Brinton; Xia Xu; Mark E Sherman; Britton Trabert; Gretchen L Gierach Journal: J Clin Med Date: 2020-01-17 Impact factor: 4.241
Authors: Eunjung Lee; April Kinninger; Giske Ursin; Chiuchen Tseng; Susan Hurley; Miaomiao Wang; Yunzhu Wang; June-Soo Park; Myrto Petreas; Dennis Deapen; Peggy Reynolds Journal: Int J Environ Res Public Health Date: 2020-01-17 Impact factor: 3.390
Authors: Eunjung Lee; Jianning Luo; Yu-Chen Su; Juan Pablo Lewinger; Fredrick R Schumacher; David Van Den Berg; Anna H Wu; Leslie Bernstein; Giske Ursin Journal: Breast Cancer Res Date: 2014-12-11 Impact factor: 8.408